SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Harold Engstrom who wrote (6735)6/1/1999 9:44:00 AM
From: scaram(o)uche  Respond to of 9719
 
Harold:

Don't know yet. Several companies are on the trail of the cells that selectively produce type I INFs. I'm enthusiastic about that approach. However, I had never considered the potential in going at the receptors.

At first blush, I'm "neutral, need more research/thought".

Rick



To: Harold Engstrom who wrote (6735)6/1/1999 10:55:00 AM
From: Vector1  Respond to of 9719
 
Harold,
Very early stage. The molecule will not be in clinical development for at least another year. They did not pay very much and I will leave the scientific assesment to those who have the expertise. However it is an indication that they plan on building more than a one drug company. I expect more acquisitions of later stage drugs.

v1


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News